Marksans Pharma Limited share price
NSE: MARKSANS · ISIN INE750C01026
Key numbers
- Market cap
- ₹ 15,269 Cr
- Current price
- ₹ 336.95
- 52-week high / low
- ₹ 351 / 155
- Stock P/E
- 29.6
- Book value
- ₹ 66.7
- Dividend yield
- 0.27%
- ROCE
- 19.0%
- ROE
- 15.2%
- Debt to equity
- 0.11
- Sales growth (3 yrs)
- 16.7%
- Profit growth (3 yrs)
- 16.2%
- 1-year return
- 98.1%
About Marksans Pharma Limited
Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamines, anti-fungal, anti-viral, laxatives, and cold and cough therapeutic areas. Its product portfolio includes plain, enteric-coated, and film coated tablets; soft gelatin and hard capsules; oral liquids; and ointments, as well as creams and liquids. The company provides its products to supermarkets, high street retailers, pharmacy chains, and wholesalers. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.
Quarterly results
Consolidated figures in ₹ crores
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 620 | 720 | 754 | 856 | 841 |
| Operating profit | 100 | 145 | 161 | 195 | 213 |
| Net profit | 58 | 98 | 113 | 148 | 157 |
| EPS (₹) | 1.29 | 2.17 | 2.50 | 3.27 | 3.47 |
Concall summary (2026-08-20)
AI summary of the earnings call transcript · tone: Positive · source document
Guidance & outlook
- Operating revenue for Q1 FY27 stood at INR840.8 crores, up 35.6% year-on-year from INR620 crores in Q1 of FY26.
- EBITDA stood at INR213 crores, compared with INR100.1 crores in Q1 FY26, representing 112.8% year-on-year growth.
Growth & demand
- Even excluding this contribution, the region grew strongly by 53.1% year -on-year.
- UK and Europe delivered INR356 crores, representing 74.7% year -on-year growth and approximately 42% of consolidated revenue.
Margins & costs
- EBITDA margin expanded to 25.3% from 16.1%, an improvement Marksans Pharma Limited August 13, 2026 of 919 basis points.
- Sequentially, EBITDA increased from INR195.4 crores, while EBITDA margin expanded by 251 basis points.
Capex & expansion
- During the quarter, we completed the acquisition of QliniQ B.V in Netherlands, which contributed approximately INR44 crores of revenue in Q1.
- While gross margin improved to 59.1% from 57.8%, an expansion of 138 basis points.
Balance sheet & cash
- The improvement reflects the benefit of higher gross margin together with operating leverage.
- While the net cash stood at INR1,031 crores, this was achieved despite the payment towards the QliniQ acquisition during the quarter.
Peers in Drug Manufacturers - General
Data for information only, not investment advice. Prices end of day.